CWA Asset Management Group LLC Invests $3.34 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CWA Asset Management Group LLC bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 151,537 shares of the company's stock, valued at approximately $3,340,000.

A number of other institutional investors and hedge funds have also bought and sold shares of TEVA. UMB Bank n.a. raised its stake in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co raised its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $50,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $52,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in Teva Pharmaceutical Industries in the second quarter worth $57,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research reports. StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average price target of $20.88.

Teva Pharmaceutical Industries Price Performance

TEVA traded up $0.57 during trading on Tuesday, reaching $21.64. 12,546,436 shares of the company traded hands, compared to its average volume of 8,900,384. Teva Pharmaceutical Industries Limited has a 12-month low of $10.83 and a 12-month high of $22.80. The firm has a fifty day simple moving average of $18.66 and a 200 day simple moving average of $17.91. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a market cap of $24.52 billion, a P/E ratio of -25.46, a PEG ratio of 0.99 and a beta of 0.73.

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.